Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Pharmacology of thermogenic drugs.

Astrup A, Toubro S, Christensen NJ, Quaade F.

Am J Clin Nutr. 1992 Jan;55(1 Suppl):246S-248S. Review.

PMID:
1345887
2.

Pharmacological and clinical studies of ephedrine and other thermogenic agonists.

Astrup A, Breum L, Toubro S.

Obes Res. 1995 Nov;3 Suppl 4:537S-540S. Review.

3.
4.

Citrus aurantium as a thermogenic, weight-reduction replacement for ephedra: an overview.

Preuss HG, DiFerdinando D, Bagchi M, Bagchi D.

J Med. 2002;33(1-4):247-64. Review.

PMID:
12939122
5.

ICI D7114: a novel selective adrenoceptor agonist of brown fat and thermogenesis.

Holloway BR, Howe R, Rao BS, Stribling D.

Am J Clin Nutr. 1992 Jan;55(1 Suppl):262S-264S. Review.

PMID:
1345891
6.

Ephedrine, caffeine and aspirin: "over-the-counter" drugs that interact to stimulate thermogenesis in the obese.

Dulloo AG, Miller DS.

Nutrition. 1989 Jan-Feb;5(1):7-9. Review. No abstract available.

PMID:
2520262
7.

Thermogenic drugs as a strategy for treatment of obesity.

Astrup A.

Endocrine. 2000 Oct;13(2):207-12. Review.

PMID:
11186222
8.

Thermogenic effects of various beta-adrenoceptor agonists in humans: their potential usefulness in the treatment of obesity.

Jéquier E, Munger R, Felber JP.

Am J Clin Nutr. 1992 Jan;55(1 Suppl):249S-251S. Review.

PMID:
1345888
9.

Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea.

Diepvens K, Westerterp KR, Westerterp-Plantenga MS.

Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1):R77-85. Epub 2006 Jul 13. Review.

10.

Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis.

Dulloo AG.

Int J Obes Relat Metab Disord. 1993 Feb;17 Suppl 1:S35-40. Review.

PMID:
8384178
11.
12.

Herbal simulation of ephedrine and caffeine in treatment of obesity.

Dulloo AG.

Int J Obes Relat Metab Disord. 2002 May;26(5):590-2. Review. No abstract available.

PMID:
12032740
13.

Clinical studies with the beta-adrenoceptor agonist BRL 26830A.

Connacher AA, Bennet WM, Jung RT.

Am J Clin Nutr. 1992 Jan;55(1 Suppl):258S-261S. Review.

PMID:
1345890
14.

BRL 35135, a potent and selective atypical beta-adrenoceptor agonist.

Cawthorne MA, Sennitt MV, Arch JR, Smith SA.

Am J Clin Nutr. 1992 Jan;55(1 Suppl):252S-257S. Review.

PMID:
1345889
15.

Present and future pharmacological approaches.

Finer N.

Br Med Bull. 1997;53(2):409-32. Review.

PMID:
9246843
16.

Combined drug treatment of obesity.

Atkinson RL, Blank RC, Loper JF, Schumacher D, Lutes RA.

Obes Res. 1995 Nov;3 Suppl 4:497S-500S. Review.

17.

Drug treatment of obesity.

Bray GA.

Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Apr;13(1):131-48. Review.

PMID:
10932681
18.

Thermogenic ingredients and body weight regulation.

Hursel R, Westerterp-Plantenga MS.

Int J Obes (Lond). 2010 Apr;34(4):659-69. doi: 10.1038/ijo.2009.299. Epub 2010 Feb 9. Review.

PMID:
20142827
19.

The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.

Arch JR.

Naunyn Schmiedebergs Arch Pharmacol. 2008 Aug;378(2):225-40. doi: 10.1007/s00210-008-0271-1. Epub 2008 Jul 9. Review.

PMID:
18612674
20.

Clinical aspects of ephedrine in the treatment of obesity.

Pasquali R, Casimirri F.

Int J Obes Relat Metab Disord. 1993 Feb;17 Suppl 1:S65-8. Review. No abstract available.

PMID:
8384185

Supplemental Content

Support Center